485 Results for "

Platelet Aggregation Inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (485)

485 Results for "Platelet Aggregation Inhibitor" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-N0677
CAS No.: 786593-06-4
Dehydroandrographolide succinate can be extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used in research for viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect. Dehydroandrographolide succinate exerts antithrombotic effect. Dehydroandrographolide succinate significantly inhibits the platelet aggregation rate (ED50 = 386.9 mg/kg) by decreasing TXB2 levels. Dehydroandrographolide succinate mitigates muscle astrophy via the Akt/GSK3β and MuRF-1 pathways .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18775
CAS No.: 110505-75-4
Synonyms: Para-topolin riboside
N6-(4-Hydroxybenzyl) adenosine (Para-topolin riboside) is an equilibrative nucleoside transporter 1 (ENT1) inhibitor and a selective agonist of adenosine A2a receptor (A2aR), and also exhibits activity against P2Y12 receptor. N6-(4-Hydroxybenzyl) adenosine reduces ethanol intake and preference, attenuates operant conditioning-induced ethanol place preference, decreases the value of ethanol-related rewards, and inhibits collagen-induced platelet aggregation. N6-(4-Hydroxybenzyl) adenosine can be used in studies related to alcohol use disorder .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-149454
CAS No.: 2738381-94-5
Purity:  99.87%
Target:  

P2Y Receptor

Research Areas:  

Cancer

P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of P2Y1 and P2Y12 with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC50 of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N3377
CAS No.: 573-44-4
Liriodendrin is an orally effective lignan compound with anti-inflammatory, antioxidant, and anti-platelet aggregation activities. Liriodendrin is isolated and extracted from Sargentodoxae caulis and Linaria vulgaris. Liriodendrin regulates the expression of genes related to inflammation and cellular metabolism by inhibiting the NF-κB, PI3K/Akt, and TLR4 signaling pathways, or by activating the PI3K-DDX18 pathway. Liriodendrin increases the expression of HSF1 and HSP27 without cytotoxicity. Liriodendrin is used in studies on ulcerative colitis, myocardial ischemia-reperfusion injury, sepsis-induced acute lung injury, and chronic endometritis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-114986
CAS No.: 67786-53-2
Purity:  ≥99.0%
Synonyms: 6-keto-Prostaglandin E1
Target:  

β-glucuronidase

Research Areas:  

Cardiovascular Disease

6-Keto-PGE1 (6-keto-Prostaglandin E1) is a biologically active derivative of PGE1. 6-Keto-PGE1 inhibits adenosine diphosphate-induced platelet aggregation. 6-Keto-PGE1 reduces cardiac afterload, decreases the accumulation of plasma myocardial depressant factor (MDF), lowers arterial blood pressure, dilates vascular beds, inhibits the vasoconstrictive response of vascular smooth muscle, and increases pulmonary compliance. 6-Keto-PGE1 directly stabilizes isolated cat liver lysosomes and significantly reduces the release of β-glucuronidase and cathepsin D. 6-Keto-PGE1 prolongs the survival time of traumatized rats and exerts protective effects through hemodynamic and cytoprotective actions. 6-Keto-PGE1 reduces central airway resistance. 6-Keto-PGE1 can be used in studies related to traumatic shock .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0910
CAS No.: 155683-00-4
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 + T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca 2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .
loading...
    loading...
Cat. No.: HY-111247
CAS No.: 87112-49-0
Ro 09-0680 is a potent inhibitor of rabbit platelet aggregation induced by Collagen with an IC50 of 6.6 μM .
loading...
    loading...
Cat. No.: HY-125053A
Purity:  99.58%
Target:  

Glycoprotein VI

Research Areas:  

Cardiovascular Disease

Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
loading...
    loading...
Cat. No.: HY-15284S2
CAS No.: 1189919-49-0
Synonyms: PCR 4099-d4
Prasugrel-d4 is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
loading...
    loading...
Cat. No.: HY-10304A
CAS No.: 163250-91-7
Purity:  98.13%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
loading...
    loading...
Cat. No.: HY-106580
CAS No.: 63394-05-8
Synonyms: ITA 104
Plafibride (ITA 104) is an orally active hypolipemic, platelet aggregation inhibitor .
loading...
    loading...
Cat. No.: HY-114564
CAS No.: 111753-73-2
Purity:  99.85%
Synonyms: E5510
Research Areas:  

Cardiovascular Disease

Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .
loading...
    loading...
Cat. No.: HY-Y1094
CAS No.: 12092-47-6
Synonyms: Chloro(1,5-cyclooctadiene)rhodium(I) dimer
Research Areas:  

Cardiovascular Disease Cancer

[Rh(cod)Cl]2 (Chloro (1,5-cyclooctadiene) rhodium (I) dimer) is an organometallic rhodium (I) dimer precursor and platelet aggregation inhibitor. [Rh(cod)Cl]2 inhibits PAF-induced aggregation in washed rabbit platelets. [Rh(cod)Cl]2 inhibits aggregation induced by PAF, Thrombin, ADP and Collagen in human platelet-rich plasma. [Rh(cod)Cl]2 acts as a catalyst precursor for the hydrogenation of aromatic hydrocarbons, phenols, olefins and BINOL derivatives. [Rh(cod)Cl]2 is used in the research of cardiovascular diseases such as thromboinflammation-related disorders, tumor metastasis and atherosclerosis .
loading...
    loading...
Cat. No.: HY-130060
CAS No.: 72710-10-2
Target:  

PKA Integrin

Research Areas:  

Cardiovascular Disease

12(S)-HETrE is a fatty acid metabolite that inhibits platelet aggregation. 12(S)-HETrE can be used in thrombosis-related research .
loading...
    loading...
Cat. No.: HY-159839
CAS No.: 2760609-74-1
Synonyms: CG-0255
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

Evategrel is a platelet aggregation inhibitor .
loading...
    loading...
Cat. No.: HY-N1717
CAS No.: 577-56-0
2-Acetylbenzoic acid, a Benzoic acid (HY-N0216) derivative, is a weak platelet aggregation inhibitor. 2-Acetylbenzoic acid inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation .
loading...
    loading...
Cat. No.: HY-19184
CAS No.: 149549-14-4
MKC-963 is an orally active and potent inhibitor targeting platelet aggregation-related pathways. MKC-963 exerts antithrombotic activity by inhibiting platelet aggregation, and can also induce autoinduction, i.e., upregulating the mRNA expression and activity of CYP3A4 enzyme to accelerate its own metabolism in vivo. MKC-963 is promising for research of platelet aggregation-related diseases (e.g., thrombosis) .
loading...
    loading...
Cat. No.: HY-P3052
CAS No.: 93674-99-8
Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect .
loading...
    loading...
Cat. No.: HY-138019
CAS No.: 2088247-61-2
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

SP-8008 is a selective shear stress-induced platelet aggregation (SIPA) inhibitor with an IC50 of 1.44 μM. SP-8008 effectively interferes von Willebrand factor (vWF) and platelet glycoprotein (GP) Ib interaction. SP-8008 exerts its antithrombotic effect by selectively inhibiting shear stress-induced platelet aggregation .
loading...
    loading...
Cat. No.: HY-119735
CAS No.: 17015-43-9
Target:  

Others

Research Areas:  

Cardiovascular Disease

Curcolone is a sesquiterpenoid that inhibits collagen-induced or arachidonic acid (AA)-induced platelet aggregation .
loading...
    loading...